Complete full enrollment in global pivotal Phase 3 chronic neutropenia clinical trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Feb 2025
- Due
- 30 Jun 2025
- Checked
- 13 Sep 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025”
What we found
Evidence strength A What the grades mean
X4 repeatedly delayed the 4WARD trial enrollment completion target from mid-2025 to Q3/Q4 2025, then Q3 2026, then year-end 2026, and it remains incomplete as of September 2026.
-
A X4 Pharmaceuticals, Inc - Form 8-K - FY2025 (Q4 2024 earnings) Revised enrollment timeline to Q3/Q4 2025 from original mid-2025 target.
-
B X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results Enrollment still targeted for Q3 2026, not yet complete.
-
D X4 Pharmaceuticals Reports First Quarter 2026 Financial Results Company still on track for Q3 2026 enrollment completion, not yet achieved.
-
D X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results Enrollment target pushed to Q3 2026 with enrollment size increased to 176 patients.
Checked 13 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you X4 Pharmaceuticals, Inc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-XFOR-000308 · Corrections policy